Check-Cap (CHEK) & Assembly Biosciences (ASMB) Head-To-Head Comparison
Check-Cap (NASDAQ: CHEK) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, earnings, profitability, analyst recommendations, institutional ownership and valuation.
This is a breakdown of current ratings and recommmendations for Check-Cap and Assembly Biosciences, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Check-Cap presently has a consensus target price of $6.00, indicating a potential upside of 209.28%. Assembly Biosciences has a consensus target price of $35.00, indicating a potential upside of 1.19%. Given Check-Cap’s higher probable upside, equities research analysts plainly believe Check-Cap is more favorable than Assembly Biosciences.
Risk and Volatility
Check-Cap has a beta of -0.35, suggesting that its stock price is 135% less volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.84, suggesting that its stock price is 16% less volatile than the S&P 500.
Insider and Institutional Ownership
19.3% of Check-Cap shares are held by institutional investors. Comparatively, 72.3% of Assembly Biosciences shares are held by institutional investors. 19.6% of Assembly Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
This table compares Check-Cap and Assembly Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Check-Cap and Assembly Biosciences’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Assembly Biosciences||$3.04 million||197.57||-$50.92 million||($2.93)||-11.81|
Check-Cap has higher revenue, but lower earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Check-Cap, indicating that it is currently the more affordable of the two stocks.
Assembly Biosciences beats Check-Cap on 6 of the 10 factors compared between the two stocks.
Check-Cap Ltd. (Check-Cap) is a clinical-stage medical diagnostics company. The Company is engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The Company’s system consists of main components, such as ingestible scanning capsule; Capsule Positioning System (CPS), a recorder worn on the patient’s back, and a personal computer (PC)-based work station for data reconstruction and image processing. The Company’s scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. Its scanning capsule employs low-dose X-rays, which allow the system to image the interior lining of the colon even when surrounded by intestinal content. Its capsule transmits information to a receiving device worn on the patient’s body that stores the information for off-line analysis.
About Assembly Biosciences
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Receive News & Ratings for Check-Cap Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.